Liljas B - Search Results

1

Matching-adjusted indirect comparison of Acalabrutinib versus Ibrutinib in relapsed/refractory mantle cell lymphoma.

Cai L, Roos J, Miranda PAP, Liljas B, Rule S, Wang M. Cai L, et al. Among authors: liljas b. J Med Econ. 2024 Oct 26:1-8. doi: 10.1080/13696998.2024.2422227. Online ahead of print. J Med Econ. 2024. PMID: 39461001 Free article.

2

Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.

Sharman JP, Miranda P, Roos J, Emeribe U, Cai L, Liljas B, Gaitonde P. Sharman JP, et al. Among authors: liljas b. Leuk Lymphoma. 2023 Jul-Aug;64(7):1243-1252. doi: 10.1080/10428194.2023.2212433. Epub 2023 May 23. Leuk Lymphoma. 2023. PMID: 37221877

3

Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States.

Munir T, Genovez V, Genestier V, Ryan K, Liljas B, Gaitonde P. Munir T, et al. Among authors: liljas b. Expert Rev Pharmacoecon Outcomes Res. 2023 Jun;23(5):579-589. doi: 10.1080/14737167.2023.2196408. Epub 2023 Apr 10. Expert Rev Pharmacoecon Outcomes Res. 2023. PMID: 36987886

4

Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors.

Gaitonde P, Chirikov V, Kelkar S, Liljas B. Gaitonde P, et al. Among authors: liljas b. Cancer Manag Res. 2022 Dec 7;14:3421-3435. doi: 10.2147/CMAR.S380857. eCollection 2022. Cancer Manag Res. 2022. PMID: 36514307 Free PMC article.

5

Welfare, QALYs, and costs - a comment.

Liljas B. Liljas B. Health Econ. 2011 Jan;20(1):68-72. doi: 10.1002/hec.1600. Health Econ. 2011. PMID: 21157833

6

The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.

Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B. Toghanian S, et al. Among authors: liljas b. Clin Drug Investig. 2010;30(3):167-78. doi: 10.2165/11531670-000000000-00000. Clin Drug Investig. 2010. PMID: 20155989

7

Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding.

Barkun AN, Adam V, Sung JJ, Kuipers EJ, Mössner J, Jensen D, Stuart R, Lau JY, Nauclér E, Kilhamn J, Granstedt H, Liljas B, Lind T. Barkun AN, et al. Among authors: liljas b. Pharmacoeconomics. 2010;28(3):217-30. doi: 10.2165/11531480-000000000-00000. Pharmacoeconomics. 2010. PMID: 20151726

8

On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected.

Liljas B. Liljas B. Eur J Health Econ. 2010 Feb;11(1):5-13. doi: 10.1007/s10198-009-0145-6. Epub 2009 Mar 3. Eur J Health Econ. 2010. PMID: 19255794

9

Can managed care organizations partner with manufacturers for comparative effectiveness research?

Luce BR, Paramore LC, Parasuraman B, Liljas B, de Lissovoy G. Luce BR, et al. Among authors: liljas b. Am J Manag Care. 2008 Mar;14(3):149-56. Am J Manag Care. 2008. PMID: 18333707 Free article.

10

On future non-medical costs in economic evaluations.

Liljas B, Karlsson GS, Stålhammar NO. Liljas B, et al. Health Econ. 2008 May;17(5):579-91. doi: 10.1002/hec.1279. Health Econ. 2008. PMID: 17787027

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters